“We want to thank…. MedWorld Advisors for their strategic relationships which helped to arrange for this deal to come together in record time…" – Eric Gjerde, President of Airon Corporation – announcing the GE / Ford / Airon Deal that brought 50,000 ventilators to production within 100 days in the early phase of the COVID pandemic. https://aironusa.com/airon-corp-teams-with-ford-and-ge-healthcare-to-fight-covid-19/Project BardDevelopment of Molecular Tools for Cancer Detection and COVID-19 TestingApril 2023Executive SummaryClifton Life Sciences (“Clifton” or “CLS” or the “Company”) is a life sciences company that has developed an innovative liquid biopsy, a molecular signature-based platform for timely cancer diagnostics. The Company’s proprietary genomic profiling combined with advanced informatics and their data management software is used to develop the molecular signature-based platform. Clifton also develops Q-PCR based liquid biopsies that aid in cancer detection, diagnosis, and monitoring. The Company is headquartered in Nevis, West Indies.The main causes of morbidity and mortality among people worldwide are chronic diseases such as cardiovascular conditions, cancer, metabolic bone diseases, and neurological diseases. Cancer alone was responsible for ~10.0 million deaths in 2020. Hence, early detection, diagnosis, and treatment of these chronic diseases is essential as it can reduce the risk of complications and improve the long-term health of individuals. Common imaging tests such as Computerized Tomography (CT) scan, bone scan, Magnetic Resonance Imaging (MRI), and X-ray are expensive and expose patients to harmful radiation, thus hindering their utility as diagnostic solutions. Liquid biopsy is a revolutionary lab test conducted on a sample of blood, urine, or other bodily fluids to identify cancerous cells from tumors, or DNA and RNA. This innovation has simplified the screening procedure for cancer, making treatment more plausible. The change in the pattern of cancer classification from clinical and histopathological to molecular has opened a more personalized outlook for tumor therapy and diagnostics. Further, the integration of AI in liquid biopsies offers the ability to identify signatures of specific disease states in multiplexed data. These methods are being used by an increasing number of studies to find signatures in many circulating biomarkers for a variety of medical conditions.The attempts to manage the rising prevalence of these chronic conditions have led to significant growth in diagnostic testing. The global diagnostic testing market was valued at $179.8 billion in 2022 and is expected to reach a value of $271.6 billion by 2027, growing at a CAGR of 8.6%. Technological advancements in diagnostic testing have paved the way for biomarker testing, which has proven to be accurate, non-invasive, and quicker, and provides early detection of cancer and neurodevelopmental disorders, amongst other chronic diseases. The global biomarkers testing market was valued at $67.0 billion in 2022 and is expected to reach a value of $125.1 billion by 2027, growing at a CAGR of 13.3%. Further, liquid biopsies are a minimally invasive alternative to tissue biopsies for cancer screening. This procedure incurs lower costs, poses minimal risk, provides quicker results, and assists in tumor heterogeneity reduction, thus encouraging the growth of the market. The global liquid biopsy market was valued at $4.7 billion in 2022 and is expected to reach a value of $9.2 billion by 2027, growing at a CAGR of 14.5%. The PCR (Polymerase Chain Reaction) segment is estimated to be one of the highest-growing segments of the market, whose growth is driven by its rapidly rising utilization such as the detection of fungal infections, and bacterial infections, genomic applications, with emphasis on precision medicine. The global precision medicine market is expected to grow at a CAGR of 11.5% from 2022 to 2027. Additionally, due to the multiple benefits of AI (Artificial Intelligence) integration in diagnostics, AI in the diagnostics market is expected to grow at a CAGR of 24.6% in the forecast period.Clifton is continuously innovating and developing diagnostic tools for various types of cancer and COVID-19. The current solution portfolio of the Company consists of RNA assay tools, algorithm-based RNA biomarker discovery, and a range of disease-specific RNA-based diagnostic assays. Clifton leverages an algorithmic approach to create diagnostic gene signatures from RNA-based biomarkers and patient data for complex heterogeneous diseases. NETest™, a 51 gene panel blood test for neuroendocrine tumors, and COVID-19 PCR Test by the Company are currently commercially available, while PROSTest™, an RNA-based diagnostic assay for the management of prostate cancer, is under development. The Company further owns multiple patents and is developing molecule-based methods to define the efficacy of tumor removal and detection of residual disease. MedWorld Advisors (MWA) is an International M&A and Commercialization Services Firm. With offices in the US and Hong Kong, and collaboration partners worldwide (including India, China, Japan, Israel, Canada, Switzerland, Germany, and the Netherlands), MWA specializes in helping healthcare SMEs achieve their strategic objectives. Based on our founders' and participating consultants' backgrounds, MedWorld Advisors brings a proven process methodology and a unique set of industry knowledge and contacts for our clients. Our credo Value = Strategic Fit + Timing® demonstrates our core objective to ensure a winning outcome for all stakeholders.BackgroundEvolution of Medical DiagnosisChronic diseases such as cardiovascular disorders, cancer, metabolic bone diseases, and neurodegenerative diseases are the leading causes of morbidity and mortality among individuals across the world. Most chronic diseases are caused by a few key risk behaviors that include smoking, consumption of alcohol, poor nutrition, and physical inactivity. In addition, the risk of acquiring a chronic disease is largely influenced by an individual’s genetics (G) and exposures (E), plus their interactions (G*E). As a result, the early detection, diagnosis, and treatment of these chronic diseases is essential as it can reduce the risk of complications and improve the long-term health of individuals.Cancer and neurological disorders represent a major public health concern as they are one of the leading causes of death worldwide. In 2020, there were an estimated 18.1 million cancer cases and nearly 10.0 million deaths (1 in 6 deaths) across the world [1][2]. The Alzheimer’s Association estimates that approximately 13.8 million people aged 65 years and above will suffer from Alzheimer’s dementia by 2050 [3]. In the U.S., people suffering from Alzheimer’s and Parkinson’s diseases cost the nation nearly $200.0 billion annually in patient care and lost productivity. The cost is estimated to increase to $1.1 trillion by 2050 [4]. The high mortality rate due to these chronic diseases can be reduced by focusing on screening and early detection and diagnosis, wherein any malignancy or precursor lesion can be identified before the onset of symptoms. However, ~50.0% of cancers are at an advanced stage when diagnosed, resulting in a low success rate of treatment [5]. Over the years, multiple approaches and methods have been used by clinicians to diagnose different malignancies in the human body. These include imaging tests, laboratory tests, and biopsies. The common imaging tests include a Computerized Tomography (CT) scan, bone scan, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) scan, ultrasound, and X-ray. Although the adoption of screening programs contributes to increased survival rates, various factors hamper this diagnostic method from reaching a higher level of efficacy. These screening and imaging tools expose patients to harmful radiation, are expensive, and require special clinical facilities and staff. As a result, these factors can eventually lead to overdiagnosis and false positive results. Due to the above limitations in a screening procedure, a tissue biopsy can be considered for histopathological evaluation and cancer diagnosis in patients. Tissue sampling has been the gold standard approach for cancer diagnosis, but it is associated with several disadvantages. It is an invasive collection procedure that does not fully represent tumor heterogeneity. Also, some tumors are not easily accessible due to their anatomical location. As a result, minimally invasive and non-invasive techniques like liquid biopsy are gaining traction for improved disease detection and early diagnosis.434721026416000Liquid BiopsyAdvancements in epigenetic profiling have allowed for novel applications of liquid biopsies for diseases without characteristic mutational profiles, including many degenerative, autoimmune, inflammatory, ischemic, and infectious disorders. These events have paved the way for a wide array of life-threatening diseases and conditions to benefit from enhanced diagnostic, prognostic, and treatment abilities through the use of liquid biomarkers: a ‘liquid biopsy’ approach.Liquid Biopsy is a laboratory test done on a sample of blood, urine, or other body fluid to look for cancer cells from a tumor or small pieces of Deoxyribonucleic Acid (DNA), Ribonucleic Acid (RNA), or other molecules released by tumor cells into a person's body fluids. This test has revolutionized the field of clinical diagnosis, offering ease in tumor sampling, continuous monitoring by repeated sampling, devising personalized therapeutic regimens, and screening for therapeutic resistance. The various analytes isolated from blood in liquid biopsy provide a wide variety of information regarding tumors. Each analyte has a specific application in tumor diagnosis, monitoring, and treatment.03429000Circular RNAs – Emerging Biomarkers in Liquid BiopsyRibonucleic Acid is a polymeric molecule essential in various biological roles in the coding, decoding, regulation, and expression of genes. Transcriptomics is the study of the entire set of RNA transcripts present in a cell population to examine gene expressions.497840012827000The global RNA analysis market is expected to grow at a CAGR of 16.6% from 2022 to 2027 [6]. Numerous predictive and prognostic gene expression assays, along with cancer biomarkers, have been in use in clinical oncology. In addition, the change in the pattern of cancer classification from clinical and histopathological to molecular has opened a more personalized outlook for tumor therapy and diagnostics. The further development of transcriptome profiling is expected to also allow for standardization and the reduction of its analysis cost, which may become the subsequent step for transcriptomics to become a standard of contemporary cancer medicine.In order to increase the feasibility of translating biomarkers and gene expression measurements into clinical practice, many approaches have been developed. From 2022 to 2030, the RNA structure and molecular dynamics market is anticipated to experience a substantial CAGR due to the medicinal value of RNA in the creation of novel drugs. Additionally, molecular dynamics is expected to develop into a flexible tool to support experimental studies of RNA structural dynamics, opening up prospects for field expansion and maximizing advantages from the molecular dynamics simulations without requiring any additional methodological developments.Artificial Intelligence (AI) and Machine Learning (ML) in Liquid BiopsyLiquid biopsy-based approaches offer many new opportunities to measure molecular biomarkers for the diagnosis, prognosis, and monitoring of diseases. AI and its ability to identify signatures of specific disease states in multiplexed data are expected to be the key technology in taking advantage of the new molecular information that microchip-based diagnostics can extract.The term "machine learning" refers to a group of computational methods that are frequently used in a variety of fields to transform a huge number of measurements into more meaningful, lower-dimensional outputs. In order to assist with disease diagnosis, prognosis, and clinical decision-making, ML algorithms have been extensively used for analyzing liquid biopsy data in recent years. These methods are being used by an increasing number of studies to find signatures in many circulating biomarkers for a variety of conditions, such as diabetes, cancer, tuberculosis, dengue fever, heart disease, liver disease, and a host of other conditions. This research uses a range of ML techniques that, in many cases, outperform the sensitivity and specificity of individual markers, such as support vector machines, decision trees, and random forests.Clifton Life Sciences SolutionThe life sciences business that Clifton Life Sciences has created and is commercializing, is an advanced blood-based molecular signature platform. This platform combines the proprietary genetic profiles of the Company with cutting-edge informatics and data management tools. This solution is an end-to-end service that can be outsourced and gives customers data, that is instantly prepared for use in clinical management based on molecular biomarkers for both diagnostic and therapeutic purposes. Market Overviewright23019300Diagnostic Testing MarketDiagnostic tests are the kinds of medical examinations carried out to assist in the recognition or diagnosis of any illness. These tests are essential for the management, monitoring, and prevention of any diseaseThe global diagnostic testing market was valued at $179.8 billion in 2022 and is expected to reach a value of $271.6 billion by 2027, growing at a CAGR of 8.6% from 2022 to 2027 [7] The rising geriatric population globally is increasing the risk of getting numerous diseases including cancer, cardiovascular diseases, obesity, neurological disorders, and diabetes is anticipated to be a high-impact rendering driver of the marketAccording to a UN report, in 2020, there were ~727 million people aged 65 years & above globally. In addition, the number of individuals aged 80 and above is projected to double by 2050, that is, to cross more than 1.5 billion [8]Based on application, the diagnostic tests market is segmented into groups such as cardiology, oncology, neurology, orthopedics, gastrointestinal, gynecology, odontology, and others. The cardiology segment is expected to lead the market due to the increase in heart patients and other cardiovascular problems around the worldAlso, based on technology, the market for diagnostic tests is segmented into molecular diagnostic tools, in-vitro diagnostic tools, and point-of-care testing tools The in-vitro diagnostic segment is expected to dominate the market since in-vitro diagnostics are more frequently utilized to test samples like blood and saliva to identify illnesses or other abnormalities. Along with the continued growth in the senior population, it is also projected that the frequency of infectious and chronic illnesses will increase during the projection periodright27178000Biomarkers Testing MarketA biomarker or biological marker is defined as a characteristic that is objectively measured and evaluated as an indicator of normal biological or pathological processes, or a response to a therapeutic interventionThe global biomarkers testing market was valued at $67.0 billion in 2022 and is expected to reach a value of $125.1 billion by 2027, growing at a CAGR of 13.3% from 2022 to 2027 [9]The major growth factors of the biomarkers testing market include the increasing significance of companion diagnostics and personalized medicine, the rising prevalence of cancer, and the increasing R&D activities funded by various public and private sector organizationsThe companion diagnostics market and personalized medicine market are expected to grow at a CAGR of 13.9% and 11.6% respectively from 2022 to 2027 [10][11]Research in the biomarkers market aids in the development of effective therapies for the treatment of various diseases such as cancer, cardiovascular diseases, immunological diseases, and neurological diseasesResearchers from Boston University received funding of $4.6 million in October 2022 from the National Institutes of Health to innovate lung cancer biomarkers [9]In the foreseeable future, the use of biomarkers in infectious disease diagnosis is projected to become increasingly significant. Also, recent technological advancements in this field have led to a rise in non-invasive testing, quicker drug development, and early diagnosisMicroRNA-based biomarkers have been detected for the diagnosis of infections, such as rhinoviruses, influenza infections, tuberculosis, HIV, malaria, Ebola, and the Hendra virus. These miRNA biomarkers promote the early detection of infectious diseasesBased on application, the market is majorly segmented into diagnostics, drug discovery and development, and personalized medicine. The drug discovery and development segment dominated the market in 2022 with a revenue share of over 32.8% [9]Biomarkers enable the characterization of patient populations and quantitation of the extent to which new drugs reach intended targets, alter proposed pathophysiological mechanisms, and achieve clinical outcomesThe personalized medicine segment is expected to register the fastest CAGR in the near future. It is an emerging practice of medicine that uses an individual’s genetic profile in order to guide decisions made regarding the prevention, diagnosis, and treatment of diseaseBased on disease management, the market is broadly segmented into cancer, cardiovascular diseases, neurological diseases, and immunological diseases. The cancer (oncology) segment dominated the market with a revenue share of over 36.6% in 2022 [9]The Cardiovascular Diseases (CVDs) segment held the second-largest market share in 2022. Cardiac biomarkers provide an enhanced understanding of the pathophysiology of CVDs. According to the WHO, nearly 17.7 million people die from CVDs annually, accounting for over 31.0% of all global deaths [9]Liquid Biopsy Market4417060408305000A liquid biopsy, also known as a fluid biopsy, is a minimally invasive alternative to a tissue biopsy. It is a laboratory test that is done on a sample of blood, urine, or other body fluid to detect cancer cells from a tumor or small pieces of DNA, RNA, or other molecules released by tumor cells into a person's body fluidsLiquid biopsies can detect Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA). A CTC is a cancer cell from the tumor that is traveling in the bloodstream and ctDNA is a DNA fragment from the tumor cell that is circulating in the bloodThe global liquid biopsy market was valued at $4.7 billion in 2022 and is expected to reach a value of $9.2 billion by 2027, growing at a CAGR of 14.5% from 2022 to 2027 [12]Liquid biopsy procedure has several advantages including rapid findings, low cost, early prognosis, tumor heterogeneity reduction, minimal risk, and non-invasivenessThe rising incidence of cancer, coupled with the increasing demand and awareness of quick and minimally-invasive diagnostic procedures are propelling the market growthGlobally, the four most common types of cancer incidents are breast cancer, lung cancer, bowel cancer, and prostate cancer. It is estimated that the annual incidence of cancer will be 28.0 million new cases by 2040 [13]Based on circulating biomarkers, the market is majorly segmented into CTCs, cell-free DNA (cfDNA), circulating cell-free RNA (cfRNA), and exosomes and extracellular vessels. At present, the CTCs segment and cfDNA segment dominate the marketDetection of CTCs, as a liquid biopsy of tumors, can be used for early diagnosis of cancers, earlier evaluation of cancer recurrence and chemotherapeutic efficacy, and choice of individual sensitive anti-cancer drugsLiquid biopsy based on cfDNA can detect cancer recurrence quickly and can also provide insights into the molecular evolution of Minimal Residual Disease (MRD) in tumor progression through molecular characterization of cfDNA, which is of great significance for the prevention and treatment of tumor recurrenceBased on technology, the market is majorly segmented into Next-Generation Sequencing (NGS) segment and Polymerase Chain Reaction (PCR) segment: Next-Generation SequencingIn 2022, the NGS segment accounted for the largest revenue share. NGS is used for determining the sequence of DNA or RNA in order to study genetic variation associated with diseases or other biological phenomenaThe growth of NGS technology is majorly driven by increasing demand in genome mapping programs, rising technological advancements in sequencing platforms, and growing emphasis on precision and personalized medicineThe global precision medicine market is expected to grow at a CAGR of 11.5% from 2022 to 2027 [14] As a part of NGS sequencing, RNA sequencing is being actively used for a variety of purposes, such as transcriptome analysis, gene expression profiling, and variant detection. This is a result of various advancements in sequencing technologies, such as increases in accuracy, speed, and read lengthPolymerase Chain Reaction The PCR segment is estimated to be one of the highest-growing segments as is it projected to grow at a CAGR of 14.9% from 2022 to 2027 [15]PCR is one of the most widely used molecular techniques in modern biology, and the adoption of the same is rising rapidly owing to its numerous purposes such as detecting fungal infections, bacterial infections, gene mapping, and other genomic applicationsGene expression, genotyping data, and miRNA are a few examples of molecular biomarkers that can be utilized to determine the stage of chronic diseases such as cancer, diabetes, and neurological disorders. Increased use of these biomarkers in disease diagnoses is expected to increase the demand for real-time PCRIn the present scenario, Digital PCR (dPCR) is being considered a breakthrough technology that provides ultrasensitive and absolute nucleic acid quantificationright535686000Artificial Intelligence In Diagnostics MarketAI in medical diagnostics makes healthcare more accessible and affordable by assisting healthcare providers in making accurate and quick treatment decisions for their patientsThis technology can be used to diagnose cancer, triage critical findings in medical imaging, flag acute abnormalities, and predict the prevalence of life-threatening diseasesThe global AI in diagnostics market was valued at $0.8 billion in 2022 and is expected to reach a value of $2.4 billion by 2027, growing at a CAGR of 24.6% from 2022 to 2027 [16]Advancements in healthcare IT infrastructure and regular technological developments in cloud storage, computer processing, and ML algorithms are supporting the integration of AI-powered systems in diagnosticsThe growth of the market is also driven by the growing need for the adoption of AI in medical diagnosis to reduce errors, the shortage of healthcare professionals, and the rising incidence rate of chronic diseasesIn addition, the growth potential in emerging economies and the growing number of cross-industry partnerships & collaborations are expected to provide significant growth opportunities for this marketMost chronic diseases are preventable if detected early, thereby, boosting the adoption rate of AI-based diagnostics, which aids care providers in devising treatment plans to prevent or delay chronic diseaseMachine learning algorithms build a model from sample inputs and use that model to make predictions. Generally, these algorithms fall into two main categories: supervised and unsupervised learning. These learning techniques are useful for specific applications within the field of liquid biopsySupervised Learning (SL) AlgorithmsIn supervised learning, the algorithm generates a model that is deployed to the state of subsequent subjects for which the true state is knownThese predictions can take the form of a 'classification problem’, identifying a set of discrete states (such as the stage of a patient's cancer), or a regression problem, across a set of continuous variables (such as the volume of a developing tumor)In these cases, algorithm training is limited by data collection and sample size, making supervised learning techniques the most usefulUnsupervised Learning (UL) AlgorithmsThese algorithms can be used to discover groups of similar examples within the data and reduce data dimensionalityIn the application of identifying tumor cells, unsupervised techniques have been used with performance approaching that of a supervised method without the need for labeled dataSimilar unsupervised approaches have also been used to identify CTCs based on genetic clustering, identify cell-free DNA of tumor origin, and classify tumor-educated platelets based on RNA expression profilesBased on components, the market is bifurcated into hardware, software, and services The software accounted for the largest market share in 2020 and is projected to grow at the highest CAGR of 36.0% during the forecast period [17]This growth can be credited to the increasing demand for AI-enabled solutions in diagnostics to deliver accurate diagnoses at the earliestBased on diagnosis type, the market is segmented into radiology, oncology, neurology & cardiology, chest & lungs, pathology, and others Neurology & Cardiology accounted for the largest market share in 2020 and is projected to grow at a CAGR of 33.5% during the forecast period [17]The development of deep convoluted neural networks and advanced algorithms for various assessments & diagnoses is driving the segment growthFuture OutlookThe field of RNA-based diagnostics and therapies is rapidly expanding, with growing interest and investment in developing targeted treatments for various life-threatening diseases. By providing a comprehensive suite of tools and services for RNA analysis and characterization, as well as a reliable and accurate PCR-based diagnostic test, Clifton Life Science's platform can aid accelerate the development of targeted treatments for cancer and neurological diseases. This can lead to better outcomes for patients and potentially reduce the burden on healthcare systems. Clifton’s advanced technology offers a unique ability to develop RNA-based biomarkers that include:Diseases that have high diagnostic complexity and are known to have limited availability of biomarkersDiseases for which patient sample banks or comprehensive genetic data are available for investigationDiseases where there is currently a reason for differential RNA expression in the liquid biomarkers for eg., blood and/or salivaMedical DisordersGlobal Prevalence (cases in 2020)Expected Prevalence in the US (cases in 2023)Pancreatic Cancer (PAAD) [18]495,77362,210Prostate Cancer (PRAD) [19]1,414,259268,490Colorectal Cancer (COAD) [20]1,880,725153,020Lung Cancer (LUAD) [21]2,206,771238,340Breast Cancer (BRCA) [22]2,261,419353,510Myeloma [23]176,40435,730Melanoma (SKCM) [24]324,63597,610Endometriosis [25]190,000,0006,500,000Neuroendocrine Tumors (NET) [26]NA12,000Ovarian Cancer (OV) [27]313,95919,880The Company after successfully developing their lead marketed offering – NETest™ (a molecular-based algorithm for the analysis of neuroendocrine tumors) is aiming to develop multiple gene expressions for applications in a wide range of areas as mentioned below:Clifton Life Sciences is presently aiming to significantly target neurology and oncology therapeutic areas as compared to others2410537528500Neurology and Oncology depict the best suitability for CLS due to the above factors and also due to their market size and fit for Clifton Life Sciences RNA-based TechnologiesClifton’s Value PropositionsClifton could provide differentiated value propositions that are expected to garner stakeholder interest in partnershipsIndications with large targeted patient populations present an appealing commercial potential for biopharma and IVD/laboratories.Continuing demand for novel tests for various hard-to-diagnose diseases is another major source of commercial attraction for IVD/laboratories.Given the device's greater scalability, lower costs, and limited Healthcare Professional (HCP) involvement, potential uses for their saliva collection device include infectious disease diagnostics for emerging markets and contact/head injury diagnostics as there are only a few tests available for traumatic brain injury. These applications present an exciting business opportunity for life sciences tool manufacturersClifton Life Science's digital RNA platform and PCR test technology along with their proprietary RNA assay tools and AI-based RNA biomarker discovery technology could potentially offer a valuable solution to biopharmaceutical companies, IVD/laboratories, and other life science organizations looking to develop targeted therapies and diagnostics for multiple terminal illnessesCLS PropositionsBiopharmaIVD/LaboratoriesLifesciences Tools ManufacturersBiopharma companies can leverage Clifton’s diagnostic technologies to manufacture targeted therapies and medicinesAlso, Clifton can assist such companies in a range of applications that include clinical trials, biomarker R&D, CDx (Companion Diagnostics) developmentThese companies can leverage Clifton’s advanced diagnostic technologies by creating an upsurge in the demand for testingAlso, a partnership with CLS can help develop, market, and monetize the clinical diagnostics of such companies, based on their own RNA platformAs these companies usually serve biopharma, academia, and IVD/ laboratories, they can leverage Clifton’s RNA assay tools ( RNA stabilizing buffer and Saliva collection device) in order to improve assay performance-57152878141Given the growing interest and investments in targeted therapies and diagnostics for cancer and neurological diseases, with the right partnerships and licensing agreements in place, Clifton Life Sciences can play a key role in advancing the field of RNA-based diagnostics and therapies.00Given the growing interest and investments in targeted therapies and diagnostics for cancer and neurological diseases, with the right partnerships and licensing agreements in place, Clifton Life Sciences can play a key role in advancing the field of RNA-based diagnostics and therapies.Relative ValuationSr.no.Target NameAcquirer NameAnnouncement DateEnterprise Value (MM)EV/RevenueEV/EBITDA1.ArcherDX LLCIntegrated DNA Technologies20-Dec-2022$48.0NANA2.Empire Genomics, Inc.Biocare Medical LLC22-Nov-2022NANANA3.Qiagen American Type Culture Collection (ATCC)04-Apr-2022NANANA4.Biogazelle NVCellCarta Biosciences Inc.14-Dec-2021NANANA5.Genomic HealthEXACT Sciences Corp.08-Nov-2019$2520.05.9x41.2x6.Ambry GeneticsKonika Minolta Inc19-Oct-2017$1000.0NANA7.RainDance TechnologiesBio-Rad Laboratories Inc.15-Feb-2017$87.0NANA8.BARD1AG SAEurogold Ltd.16-June-2016$9.1NANA9.Cynogen Inc.Rosetta Genomics Ltd.14-Apr-2015$3.50.5xNA10.Silicon Biosystems SpAMenarini Industries11-Sept-2013NANANACompetitive LandscapeCompanyDescriptionTargeted Healthcare Concerns60325-28702000Ambry GeneticsFounded in 1999, Ambry Genetics is a healthcare company conducting genetic testing to screen and diagnose cancer, epilepsy, and rare diseases. The company is headquartered in Los Angeles, USHereditary cancer and cardiovascular diseaseNeurodevelopmental disordersEpilepsyRare diseases36449010477500Biocept, Inc.Founded in 1993, Biocept is a biotechnology company using cell separation technology for early detection, diagnosis, and monitoring of cancer. The company is headquartered in San Diego, USDetection of cancer biomarkers using cerebrospinal fluid samplecenter-58102500Cardiff Oncology, Inc.Founded in 1999, Cardiff Oncology, previously known as Trovagene, is a clinical-stage oncology therapeutics company that identifies resistance and system response to treatment. The company is headquartered in San Diego, USLeukemiasLymphomasSolid tumor cancers302895-21907500Exact Sciences, Corp.Founded in 1995, Exact Sciences is a molecular diagnostic company focused on colorectal cancer. The company is headquartered in Great Lakes, US and recently acquired Genomic Health, Inc., a genomic-based diagnostic testing companyHereditary cancerColorectal, breast, and liver cancerMolecular residual diseaseMulti-cancer detectionExai Biocenter-52006500Founded in 2021, Exai is an AI-based biotechnology company conducting liquid biopsies for the early and accurate detection of cancer, using RNA from a simple blood sample. The company is headquartered in San Francisco, USCancer detection through orphan non-coding RNAsGenecentric Therapeuticscenter-61595000Founded in 2011, Genecentric Therapeutics develops and commercializes RNA-based molecular diagnostic tests for oncology. The company is headquartered in North Carolina, USTumor and Immune Micro-environmentTherapy selection for cancer patients using advanced computational biology informaticsGenXPro GmbHcenter-71628000Founded in 2005, GenXPro is a biotechnology company created by molecular biologists that provide next-generation sequencing and qPCR solutions based on both, DNA and RNA. The company is headquartered in Frankfurt, Germany Cancer detection through liquid biopsyPrecision MedicineAll life sciences analysiscenter255270Guardant Health, Inc.Founded in 2012, Guardant Health is a precision oncology company that is focused on early diagnostics and effective management of early and late-stage cancers through testing and analytics. The company is headquartered in California, USCancer care through precision Oncologycenter17335500MDxHealth SAFounded in 2003, MDxHealth is a molecular diagnostic company that develops epigenetic tests for cancer assessment and personalized treatment of patients. The company is headquartered in Los Angeles, US Prostate cancer using their methylation-specific PCR platformInfectious diseasesMenarini Silicon Biosystemscenter-51943000Founded in 2005, Silicon Biosystems, a biomedical company, was acquired by The Menarini Group in 2013. They enable rare cell analysis with single-cell precision for cancer diagnostics. The company is headquartered in ItalyOncology Prenatal Diagnosiscenter-23622000Myriad Genetics, Inc.Founded in 1991, Myriad Genetics is a personalized medicine company developing genetic testing using molecular diagnostics to accurately diagnose and assess the risk of cancer and mental disorders. The company is headquartered in Utah, USHereditary cancerAll types of cancersPrenatal testingMental Healthcenter21018500Natera™Founded in 2004, Natera is a biotechnology company that conducts cell-free DNA testing for oncology, women’s health, and organ health. The company is headquartered in California, US OncologyPrenatal testing – Women’s healthOrgan Healthcenter12255500QiagenFounded in 1986, Qiagen, now acquired by the American Type Culture Collection is a molecular diagnostics and life sciences company that uses automation and assay technologies. The company is headquartered in the Netherlands Chronic diseasesCOVID-19Tuberculosiscenter22606000RNA Diagnostics Inc.Founded in 2010, RNA Diagnostics is a cancer diagnostics company that is building a platform of predictive biomarkers to assess the efficacy of treatments in cancer patients. The company is headquartered in Ontario, CanadaCancer Treatment Individual platform for breast cancer treatment validationcenter-56451500Sysmex InosticsFounded in 2008, Sysmex Inostics is a molecular diagnostics company that conducts blood-based biomarker analyses for physicians, clinical trials, and research. The company is headquartered in Hamburg, GermanyCancer diagnostics and other rare diseasesCompany OverviewClifton Life Sciences LLCClifton Life Sciences is a life sciences company headquartered in Nevis, West Indies, that has developed an innovative liquid biopsy, molecular signature-based platform and is presently in the process to commercialize the sameFounded in 2014 as a spin-off from Yale University, the Company provides a diagnostic mix of expertise in oncology, gastroenterology, bronchopulmonary, neuroendocrinology, and biomathematicsThe molecular signature platform offered by Clifton Life Sciences combines the Company’s proprietary genomic profiles with their advanced informatics and data management softwareThe Company develops Q-PCR based liquid biopsies that aid in cancer detection, diagnosis, and monitoring. The testing components of these tests are blood and saliva with the principal focus being on solid tumors. These blood PCR-based tests exhibit a >90.0% sensitivity and specificityAt present, the Company has a proven track record in the development of peripheral blood signatures for neuroendocrinology and prostate cancer diagnosis and managementIn the near future, they aim to identify and develop peripheral blood markers for detecting pancreatic cancer, prostate cancer, colorectal cancer, lung cancer, breast cancer, myeloma, melanoma, and endometriosis698574612500In order to validate biomarkers for disease assessment and targeted therapeutic development in cancer and other diseases, the Company has successfully partnered with pharmaceutical and biotechnology companies. These partnerships provide the foundation for the development of companion diagnostic tests in conjunction with the partners’ targeted therapeutics-5143510886940Some of the selected global partners of Clifton Life Sciences are:Wren LaboratoriesWren Laboratories is a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited liquid biopsy-focused molecular diagnostic laboratory in Branford, ConnecticutThe Company is a 100.0% held subsidiary of Clifton Life Sciences. Their approach for cancer detection and diagnosis is the PCR testing of target genes using saliva and blood as the principal testing compartments. The resultant output for the same is a Multianalyte Assay with Algorithmic Analysis (MAAA) Solution OverviewClifton Life Sciences leverages technological and scientific innovations in order to create diagnostic tools for the assessment of various types of cancer and COVID-19. The Company develops blood-based assays that function as liquid biopsies for solid tumors1365663789466OncologyNon-OncologyLeverage Saliva 00OncologyNon-OncologyLeverage Saliva 1253490420497000125349040373300012522203865880006032817387953300245300520624800057157004050The current solution portfolio of the Company consists of RNA assay tools, algorithm-based RNA biomarker discovery, and a range of disease-specific RNA-based diagnostic assays. They offer a robust range of marketed and pipeline RNA-based diagnostic tests that are primarily used in the oncology space and endometriosis:559054085090Marketed00Marketed199453585090In Development00In DevelopmentAt present, Clifton Life Sciences has commercially available tests for both neuroendocrine tumors and COVID-19. These tests are NETest™ and COVID-19 PCR Test respectivelyNETest is a blood-based test that utilizes a panel of 51 genes and aids in the diagnosis of neuroendocrine tumors. As a part of this test, a patient risk score is provided that quantifies the degree of tumor activityThe saliva assay tools offered by Clifton Life Sciences can be used with the NETest, COVID-19 saliva test, and endometriosis test, whereas the fingerprick device can be used for oncology Dx (Diagnostics) testsSaliva assay tools facilitate the collection of patient saliva samples for RNA measurements, storing, shipping, and testing. This tool comprises a saliva collection tube with an ergonomic mouthpiece and a RNA buffer embedded in the lid, in order to prevent the exposure of the same to patientsIn addition to the NETest™, Clifton Life Sciences is developing PROSTest™, which is an RNA-based diagnostic assay that aids in improving the management of prostate cancer. Also, there are multiple tests in development for different types of cancers and chronic diseases as mentioned aboveOverall, the RNA signature algorithms and sample collection tools are the underlying components of Clifton Life Sciences’ disease-specific diagnostic testsThe Company’s ApproachAs an essential part of the central dogma, RNA delivers genetic and regulatory information and reflects cellular states. The RNA molecules are able to serve as biomarkers for the diagnosis and prognosis of various diseases, including cancer and neuropsychiatric disorders419105753100Clifton Life Sciences leverages an algorithmic approach in order to create diagnostic gene signatures from RNA-based biomarkers and patient data. The Company follows a comprehensive approach that allows the development of such gene signatures for complex heterogenous diseases:The RNA signature algorithm comprises the following components:RNA expression patterns and clinical data from databasesAlgorithms trained to differentiate between disease statesQuantitative scoring systems that convey diagnostic and prognostic insights65112903671060Overview of Steps Followed in the ApproachGenerate HypothesisIn the initial phase of this approach, various databases are identified for the generation of RNA signatures. Also, evidence is gathered that supports the rationale for RNA-based testing in peer-reviewed literatureGenerate RNA SignaturesIn the next step, RNA expression signatures are generated that identify a particular disease state within an indicationDemonstrate Clinical ValidityPost the above steps, RNA expressions are validated in retrospective studies and/ or “known” samples Demonstrate Clinical UtilityIn the last step, clinical utility data for the validated RNA expressions is generated, demonstrating the actionability of the same for disease diagnosis and possible treatment By following the above approach, Clifton Life Sciences aims to generate the demand for sample collection tools and RNA signature algorithms, which are the underlying components of the Company’s various tests. In order to achieve as well as cater to this demand, the Company plans to increase awareness and increase the capacity for the same146051692910TBU0TBU196853039745TBU0TBU203204369435TBU0TBU215905710555TBU0TBU171457053580TBU0TBU22860353060TBU0TBU1337945169481513366753039745133667543726101337945353060 1336675571754013366757047230Executive Team (TBU)Intellectual Property PortfolioSr. No.Application No./Patent No.Filling DateTitleStatus1JP2020175701A10/20/2020Compositions, methods and kits for diagnosis of gastroenteropancreatic neuroendocrine neoplasmActive216 / 253,697US16/253,6971/22/2019Methods for colon cancer detection and treatmentActive3ES18731615T5/21/2018Melanoma Screening ProceduresActive4US17/501,16810/14/2021Chemical compositions and methods of usePending5US17/490,4339/30/2021Chemical compositions and methods of usePending6CA3154045A10/8/2020Compositions, methods and kits for biological sample and RNA stabilizationPending7US17/065,67510/8/2020Compositions, methods and kits for biological sample and RNA stabilizationPending8AU2019209436A1/22/2019Methods for colon cancer detection and treatment monitoringPending9US16/203,80311/29/2018Predicting peptide receptor radiotherapy using a gene expression assayPending10CN201580061761.0A9/15/2015Composition, method and kit for diagnosing stomach and intestine pancreas neuroendocrine tumorsPending11PCT/US2021/05323310/1/2021Biofluid self-collection and processing devicePublished(WO 2022/072876 A1)12PCT/US2019/0188782/21/2019Methods for prostate cancer detection and treatmentPublished(WO 2019/165021 A1)13BR112020008680-0A11/29/2018Prediction of peptide receptor radiotherapy using a gene expression assayPublished(WO 2019/108734)14PCT/US2018/06296411/29/2018Predicting peptide receptor radiotherapy using a gene expression assayPublished(WO 2019/108734 A1)15PCT/US2015/0502749/15/2015Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasmPublished(WO 2016/044330 A1)Strengths of Clifton Life Sciences’ Market Opportunity:Novel Solution: Clifton Life Sciences develops blood-based assays that function as liquid biopsies for solid tumors. This solution offers a superior alternative to the existing tissue biopsy method (gold standard)With the help of RNA-based diagnostic assays and RNA signature algorithms, the Company’s researchers have identified and validated gene markers for breast, colon, lung, pancreatic, prostate, and neuroendocrine cancers from non-invasive peripheral blood (venous and fingerprick) samplesStrong Intellectual Property Portfolio: The Company’s intellectual property portfolio consists of various active and pending patents and multiple trademarks. These patents are filed in the US, Europe, Brazil, China, India, Japan, South Korea, Israel, Australia, Hong Kong, South Africa, and Switzerland Proven Clinical Results: Clifton Life Sciences’ solution has been a part of multiple successful clinical trials. For instance, the NETest™ has been a part of 14 independent validation studies and 45 peer-reviewed studiesIndustry Partnerships: Since the Company’s inception, they have partnered with over 61 organizations. These partnerships have helped them in identifying and validating gene signatures for various cancers and other chronic diseasesWeakness of Clifton Life Sciences’ Market Opportunity:Untested Waters: The disruption that the Company brings requires mass acceptance and adaptation from healthcare facilities, biopharma companies, and IVD and testing laboratoriesHighly Competitive Market: With current offerings only in the field of oncology and multiple tests in development for various other medical disorders, there is a high possibility of established competitors offering new technologies and diagnostic solutions, which might reduce the size of the addressable market for Clifton Life Sciences About MedWorld AdvisorsMedWorld Advisors (MWA) is an international service organization based in Andover, Massachusetts, USA. MWA is dedicated to creating value for all stakeholders as we create value for our clients thru our professional offerings. MWA unlocks client value through our trademarked MedWorld 360 Value Optimization Program and unleashes client value thru our M&A Services (MWA Sell Side and MWA Buy Side) and create growth through our commercialization network. Our target clients are typically mid-market corporations ($5M to $200M) and pre-revenue emerging technology companies focused within the Med Device, MedTech, Biotech, Life Sciences and Healthcare Industries. As this industry is truly global, we believe this unique vertical industry focus offers MWA a true competitive advantage to create value for our regional and international clients.Over 100 years of Industry Relationships Among the Consulting PartnersInternational M&A Advisory Firm with HQ in Boston, MA, USAFocus on Small to Mid-Size Companies in MedTech, Med Device, Biotech, & Life Sciences ($5M to $200M)Proven ability to sell and/or license emerging technologies by MWA Founders and ConsultantsA seasoned team of experts with experience in M&A and Growth GenerationWe have a Global Scope - Consulting Partners in the U.S., Europe (Germany, Switzerland, Netherlands, Denmark), Israel, Asia (Hong Kong, China, India), Africa, Canada, and South AmericaOur Core Values:Our Industry Relationships Based on Trust and Integrity are Key to YOUR ValueWe Treat our Clients as We Want to Be TreatedRespect for Your Goals and ObjectivesProtect Your Confidentiality as AppropriateSensitive to Your Needs Thru the ProcessDo What's Right for All PartiesWe Value Long-Term Relationships!We Get to Know Your Business Like It's Our OwnWe know our business:In most cases, we have direct access to the key touchpoints for strategic partnerships and M&A deals. In select cases where we don't, we are always no more than a single contact removed from those people, and our contacts are glad to refer us because of our trust relationshipsTrust and Integrity: Confidentiality is key in everything that we do for our clients. We know that this is crucial to any deal we are engaged in. We live Integrity—more than simple honesty; it's the key to our long-term success.Create Value: Our Offerings are unique. Ultimately it is about creating value for our clients. Our unique strategy-driven process and focused knowledge of the medical industry is key in achieving successful outcomes. We really get to know our client's business inside and out. Our advisors have operating experience as well as M&A, IP, and finance.One Global Network: In the world of M&A and commercialization, understanding and knowing how to do business globally is key. We have a truly international network.Give Back: Our Industry is not known for its heart. We believe that the world of Value Growth and M&A is highly intense and needs to be appropriately financially driven! And success should be rewarded with a "heart" to include others. Giving back is a core value that blesses both the giver and the receiver. We should never forget those who need a hand-up. Ask us about what we support. We Create Value for your Medical Industry BusinessMeet the Team: The MedWorld Advisors team are individuals who have a very strong background in the Med Device and MedTech Industries while also having experience and connections in the Biotech, Life Sciences and Healthcare Segments. They also have been involved in a number of mergers and acquisitions along the years while working for Fortune 500 companies and smaller entities. Their knowledge and trail of success in setting and implementing strategies, strategic alliances and M&As worldwide is what prompted their decision to go out on their own and fill the niche for Mid-Market companies who, in these industries, very often lack the M&A experience or the networks that are important in successfully selling or acquiring entities. The Founders: The Board of Advisors:Over 25 to 30 years of M&A Experience on an average per advisors Includes Deals ranging from $1 million to $3 billion Mid-Market Specialists with a focus on Deals between $5M and $200MExtended MWA Team Completes Approximately 30 – 40 M&A Deals per YearThe team is comprised of M&A Advisors, M&A Lawyers, IP and R&D Experts, Medical Doctors, C-Level executives, all with broad, International M&A Experience. MWA Executive M&A Experience includes having worked in key positions at GE, Covidien (Medtronic), Becton Dickinson, Draeger Medical (just to name a few.)Leveraging A Global Network of Valuable Industry Relationshipscenter37274500Some of The Healthcare Strategics The MedWorld Team Has Completed Deals WithYour Key Dedicated MWA Advisors for Clifton Life Sciences LLC (Plus the Global Network):Dave Sheppard"John, Michael & fellow board members: My experience with Dave and MedWorld Advisors has been very positive. I cannot recommend them highly enough….. I have confidence in Dave's integrity in providing an honest assessment….." – CEO of Project Gold in his recommendation of MedWorld Advisors to a potential new client.Mr. Sheppard has been a leader in the Medical Device Industry for more than 30 years. His experience includes positions such as GM and VP, as well as high impact sales and marketing leadership roles at Major 500 Corporations (Covidien, Bard, Cooper and Ciba). His achievements also involve work at startup organizations (including working pre-IPO on a successful IPO company). He has become an expert in delivering both In-Organic and Organic Growth for companies of all sizes in global environments. He has successfully obtained EBIT growth thru successful M&A activities. His worldwide results included completing distribution and licensing deals with international businesses, comprising of Major Fortune 500 companies (i.e., GE, Philips, Siemens, etc.) as well as smaller entities. These experiences have led to a global network of contacts with channel partners, large and small. Dave has been involved in "go-to-market" strategies on every major developed continent (Europe, Asia, Africa, Australia, North and South America). As Managing Director at MedWorld Advisors, Dave is focused on inorganic (thru M&A business development), strategic alliances, organic growth, and EXIT Strategies for the Med Device, Biotech, and OEM MedTech companies.For M&A, the goal is to help emerging technology and middle-market companies maximize their VALUE with their EXIT Strategy and/or achieve SUCCESS with their acquisition Strategy. For Growth companies, the goal is to collaborate and lead the strategic development of client organizations. The aim is to create a strategic plan that delivers tactical actions which lead to exceeding organizational objectives for short- and long-term growth.At MedWorld Advisors, Dave works with clients focused on creating value thru organic and inorganic growth, international channel development and getting companies on the market. For M&A, he helps sell side clients to maximize value thru obtaining the right strategic and/or financial partners into the process. Organically, he creates value as he collaborates with the management of client companies as he creates tactical execution plans that help exceed organizational objectives for short- and long-term growth. For Clifton Life Sciences LLC, Dave specifically will add value through:M&A Sell Side: Dave's experience in M&A and contract manufacturing (including his time as Global Leader for OEM Business Units) allowed him to develop and maintain key industry relationships globally, including:Owens & MinorMedlineCardinalFreudenbergTeleflexCarlisleMolexGetingeVyaireBD / BardB.BraunMcKessonElcamSmithsGEPhilipsMedtronicMindrayJ&JOver 100 companies worldwideWith 20,000 LinkedIn contacts"C-Suite" Writer for MPO Magazine"MedTech Mindset" Contributor for Today's Medical Developments This combination leaves Dave VERY connected in the MedTech IndustryDave is dedicated to the success of the MedTech, BioTech, Life Science and Healthcare Industries and the Companies involved within it! He sincerely believes that each of our accomplishments contributes to all of our success!"…and we've been working with Dave Sheppard (of MedWorld) ever since last year…thanks to your introduction. He's been invaluable and a key component of how we got this… (multi-million dollar) deal done. I will always remember our interaction as one of the pivotal moments of our Company and our foundation for success" – CEO of Project Titan in unsolicited email to the individual who referred Dave to him.David CheungBased in Hong Kong, David has over 20 years' experience in the medical devices business. His location and focus on the Asian Markets for MedWorld Advisors provides a unique value for our clients seeking to expand their potential international acquirer base to include Asia.He has worked across healthcare sectors includes working with devices in many MedTech sectors. He has an extensive background in deal-making thru his time at acquisitive companies like Tyco Healthcare and Covidien. He understands OEM relationships as many of his roles for Multinational companies included managing B2B OEM customers.His work carried him through many facets of a medical device's product lifecycle starting from strategic planning (market needs evaluation, business opportunity and potential forecasting), project financing and approval, product design and development, commercial manufacturing, market testing and validation, product launch to end of life and replacement planning. This was done on a Global to Asian focus but also more recently in the reverse direction as well. The relationships he built from this encompasses Clinical, Legal and Financial professionals, Physicists, Engineers, Designers, End-users, OEM / channel partners and Sales and Marketing experts.David is a proven dealmaker. His experience in B2B OEM business along with his regional strategic relationships (China, Taiwan, and Japan) and channel expertise will bring value to the MWA team as we maximize the EXIT opportunity for Clifton Life Sciences LLCDaniel Sheppard"I would like to thank…you for your perseverance and your support over the past year. XXXX and I are thrilled with the outcome…. Thank you very much!!" – CEO of Project MedocDaniel joined MedWorld Advisors in 2016 as a valuable asset in managing deal processes. Coming from a financial background with process and project management experience, Daniel's unique skills have proven invaluable in managing dynamic and fast paced M&A processes. His creative and calculated M&A process inputs have guided past MWA clients to not only solidify company value, but also maximize value creation that has exceeded client expectations.In 2020, Daniel helped advise a medical device contract manufacturer to a successful exit in the midst of a challenging year due to the pandemic. Not only was Daniel able to assist the client in achieving 2x their valuation prediction, but he also ensured no diminished value due to Covid lockdowns interrupting processes in all industries. In fact, the client was also able to increase his valuation due to positive updates in the Company's business.Florence Joffroy-Black Ms. Florence Joffroy-Black is a proven Medical Device Executive, with expertise in international markets for more than 25 years. Born in France and now living in the U.S., she truly has global presence, knowledge and insight. She is skilled in setting marketing strategies for both inorganic and organic growth. Her worldwide results include launching successful product lines around the world, setting and implementing expansion strategies completing integration of M&A as well as implementation of new innovations and product introductions. These experiences have led to a global track record of success for both large and small corporations where both inorganic and organic growth goals were met and often exceeded.Florence has been involved in "go-to-market" strategies on every major developed continent (Europe, Asia, Africa, Australia, North and South America). Her contributions have resulted in her business group going from being an acquired entity to being the driving force for a completely integrated product line across all of a Multi-Billion Corporate portfolio of products.At MedWorld Advisors, due to her international background and industry contacts, Florence has led the MedWorld team to successfully engage in cross-border M&A activities – enhancing the EXIT opportunities for our clients. These have included potential buyers from Germany, Sweden, France, Italy, and Israel. PROCESS:MedWorld Advisors Will Create and Maximize Exit Value for Clifton Life Sciences LLC as Follows:Exit Strategy and Exit Success:First 30 Days of Process Engagement (April 1 – April 30):Obtain key stakeholder views on parameters which govern decision making on potential deals and partners, and align on expectations for the eventual exitPerform Pre-Diligence Activities to Ensure Future Process SuccessPrepare non-confidential teaserPrepare strategic confidential information memorandum (CIM)Identify and Target Strategic PartnersCritical Value Note: MWA will use its understanding of target acquirers to identify and rank the most likely acquisition partners for the CompanyDay 30 - 90 of Process Launch (May 1 – June 30):Engage Key Contacts at TargetsDays 90 - 120 of Process Launch (July 1 – July 31):Obtain Expression of Interests ("EOI") or Letters of Intents "LOI" for Clifton Life Sciences LLC Stakeholder Review:Critical Value Note: First, stimulate multiple interest by customizing the strategic targeting. Then, use MWA "Competitive Process" to Obtain Maximum Value in BidsDays 120 - 150 of Process (August 1 – August 31):Work with the Clifton Life Sciences LLC’s Team to negotiate maximum value opportunity with key interested partiesDays 150 - 240 of Process (Sept 1 – Nov 30):Exit / Close Transaction:Critical Value Note 1: Ensure Clifton Life Sciences LLC DOES NOT lose value in the diligence process (as commonly occurs in many deals).Critical Value Note 2: We will work with you on a partner-by-partner basis to evaluate deal pros and cons. MWA will manage relationships with key potential acquirers to ensure 1st, 2nd and even 3rd choices "stay in the game" as long as feasible to maximize final stakeholder value for Clifton Life Sciences LLC StakeholdersPost Transaction Execution:MedWorld Advisors will work with both seller (Clifton Life Sciences LLC) and buyer (TBD) to ensure a smooth post-transaction transition plan is in place to ensure a positive outcome for all parties.MedWorld Advisors Fee Proposal:Fee Proposal for Discussion:We propose the following fee structure which we believe will align MWA's interests with those of Clifton Life Sciences LLC’s stakeholders to the maximum extent possible:Option 1:Market Clifton Life Sciences LLC and Assist with Exit to Strategic Acquirer or Financial Buyer:USD $XX One-Time Retainer Fee + Company Approved ExpensesFor successful M&A transactions:X% of the Transaction Value for transactions representing up to $XX Mil USDX% of the Transaction Value between $XX Mil USD & $XX Mil USDX% of the Transaction Value between $XX Mil USD & $XX Mil USDX% of the Transaction Value above $XX Mil USDOption 2:Market Clifton Life Sciences LLC and Assist with Exit to Strategic Acquirer or Financial Buyer:USD $XX One-Time Retainer Fee + Company Approved ExpensesFor successful M&A transactions:X% of the Transaction Value for transactions representing up to $XX Mil USDX% of the Transaction Value between $XX Mil USD & $XX Mil USDX% of the Transaction Value between $XX Mil USD & $XX Mil USDX% of the Transaction Value above $XX Mil USDOption 3:Market Clifton Life Sciences LLC and Assist with Exit to Strategic Acquirer or Financial Buyer:USD $XX One-Time Retainer Fee + Company Approved ExpensesFor successful M&A transactions:XX% of the Transaction Value for all transactionsSummary:MedWorld Advisors is excited to present our capabilities to assist Clifton Life Sciences LLC’s stakeholders achieve their objectives to maximize value thru this Exit Process. We believe we are uniquely positioned to help Clifton Life Sciences LLC achieve a successful outcome!MEDWORLD ADVISORS WILL WORK GLOBALLY TO ACHIEVE THE KEY DESIRED OUTCOMES FOR Clifton Life Sciences LLC!Disease-specific RNA DataThe Company identifies gene clusters that are differentailly expressed between disease states, by leveraging a deep understanding of disease-specific regulatory networksPatient DataThe Company's platform incorporates demographical and clinical patient data, which allows their gene expression data to be correlated to the disease statusMulti-algorithmic ApproachBy utilizing AI and ML agorithms, the Company's platform supports the development of a highly reliable and accurate RNA expression gene signature for multiple diagnostic applicationsThis in turn allows CLS to go beyond simple diagnostics and also inculcate prognostic, predictive, and monitoring technologies in their platformResearch Use - Discovery PhaseWellness Panel: Pan-CancerPSMA Predictor: Pancreatic CancerResearch Use - Requires ValidationPancreatic Cancer TestInvestigational UseFDA-cleared and/or LDTNETest™: Neuroendocrine TumorsEndometriosis TestPROSTest: Prostate CancerNOMA Test: MelanomaPRRT Toxicity: Neuroendocrine TumorsImmunotherapy Response TestCOLOTest: Colorectal CancerBreast Cancer TestLOMATest: MyelomaLung Cancer TestPrredictor (PPQ): Neuroendocrine TumorsSwab/ Nasopharyngeal Test: COVID-19Saliva Test: COVID-1945 Peer Reviewed Studies The approach and solution offered by Clifton Life Sciences is supported by extensive publicationsOver 61 PartnershipsThe Company has an extensive trans-continental network of colloborating institutions~4,480 Samples Run AnnuallyTheir CLIA-certified laboratories have the potential to optimize the number of samples that can be tested 0.359450.373130.636620.576660.301260.365890.624520.47883CAGR: 13.3%00.19590.34960.32768$ in billionsLiquid BiopsyCTCs(Circulating Tumor Cell)ctDNA/ miRNA(circulating tumor DNA/ micro RNA)Tumor ProteinsExosomesSignificant evidence for RNA differences in disease statesAvailability of extensive databases of genomic dataThese areas have diagnostic complexity and lack confirmatory diagnostics or patient stratification tools0.362620.36570.62830.610310.303820.387410.627080.50034CAGR: 14.5%00.15140.34960.29139$ in billions0.357840.404250.623420.693960.294240.438550.61750.55148CAGR: 24.6%00.15140.34960.29139$ in billions0.359450.34920.63260.525560.309990.318160.633250.4311CAGR: 8.6%00.140950.34960.27273$ in billionsEpigenetic ChangesTumor HeterogeneityGene RearrangementsMolecular DiagnosismRNATherapeutic ResistanceCopy Number Alterations (CNAs)RNA Splice variantNon-coding RNAMetabolite Profiling23653759545676Value = Strategic Fit + Timing®00Value = Strategic Fit + Timing®31759545294MedWorld Advisors® ConfidentialDo not share without prior approval from MedWorld Advisors00MedWorld Advisors® ConfidentialDo not share without prior approval from MedWorld Advisors236855010210800Value = Strategic Fit + Timing®00Value = Strategic Fit + Timing®3904810206355MedWorld Advisors® ConfidentialDo not share without prior approval from MedWorld Advisors00MedWorld Advisors® ConfidentialDo not share without prior approval from MedWorld Advisors PAGE \* MERGEFORMAT 2-114300-3873500CTCs(Circulating Tumor Cell)ctDNA/ miRNA(circulating tumor DNA/ micro RNA)ExosomesTumor ProteinsLiquid BiopsyEpigenetic ChangesTumor HeterogeneityGene RearrangementsMolecular DiagnosismRNATherapeutic ResistanceCopy Number Alterations (CNAs)RNA Splice variantNon-coding RNAMetabolite ProfilingiVBORw0KGgoAAAANSUhEUgAAAU8AAAHQCAIAAACun38zAAAAAXNSR0IArs4c6QAA9EVJREFUeF7s